Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi, et al.
Molecular Cancer Therapeutics (2014) Vol. 13, Iss. 11, pp. 2547-2558
Open Access | Times Cited: 117

Showing 1-25 of 117 citing articles:

Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina, Nicholas C. Turner
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 318-332
Closed Access | Times Cited: 678
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Eric G. Bluemn, Ilsa M. Coleman, Jared M. Lucas, et al.
Cancer Cell (2017) Vol. 32, Iss. 4, pp. 474-489.e6
Open Access | Times Cited: 639
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
International Journal of Molecular Medicine (2016) Vol. 38, Iss. 1, pp. 3-15
Open Access | Times Cited: 340
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal, Lei Shi, Leah Y. Liu, et al.
Cancer Discovery (2019) Vol. 9, Iss. 8, pp. 1064-1079
Open Access | Times Cited: 319
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 299
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai, Zhan Zhou, Zhuchu Chen, et al.
Cells (2019) Vol. 8, Iss. 6, pp. 614-614
Open Access | Times Cited: 240
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta, Roberto Borea, Andreia Coelho, et al.
Critical Reviews in Oncology/Hematology (2017) Vol. 113, pp. 256-267
Open Access | Times Cited: 188
Therapeutics Targeting FGF Signaling Network in Human Diseases
Masaru Katoh
Trends in Pharmacological Sciences (2016) Vol. 37, Iss. 12, pp. 1081-1096
Closed Access | Times Cited: 186
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach
Marco Presta, Paola Chiodelli, Arianna Giacomini, et al.
Pharmacology & Therapeutics (2017) Vol. 179, pp. 171-187
Closed Access | Times Cited: 183
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies
Mohamed R. Akl, Poonam Nagpal, Nehad M. Ayoub, et al.
Oncotarget (2016) Vol. 7, Iss. 28, pp. 44735-44762
Open Access | Times Cited: 179
Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities
Dengdi Hu, Zhaoqing Li, Bin Zheng, et al.
Cancer Communications (2022) Vol. 42, Iss. 5, pp. 401-434
Open Access | Times Cited: 149
Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, et al.
Cancer Treatment Reviews (2021) Vol. 95, pp. 102170-102170
Open Access | Times Cited: 136
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue, Yukun Li, Xiaojuan Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 113
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges
Claudia Maria Ascione, Fabiana Napolitano, Daniela Esposito, et al.
Cancer Treatment Reviews (2023) Vol. 115, pp. 102530-102530
Closed Access | Times Cited: 106
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 57
Recent Advances in the Development of Indazole‐based Anticancer Agents
Jinyun Dong, Qijing Zhang, Zengtao Wang, et al.
ChemMedChem (2018) Vol. 13, Iss. 15, pp. 1490-1507
Closed Access | Times Cited: 129
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Jaya Julie Joshi, Heather Coffey, Erik Corcoran, et al.
Cancer Research (2017) Vol. 77, Iss. 24, pp. 6999-7013
Open Access | Times Cited: 123
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
Teresa Helsten, Maria Schwaederlé, Razelle Kurzrock
Cancer and Metastasis Reviews (2015) Vol. 34, Iss. 3, pp. 479-496
Open Access | Times Cited: 121
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
Timothy P. Heffron
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 22, pp. 10030-10066
Closed Access | Times Cited: 119
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
Robert Roskoski
Pharmacological Research (2019) Vol. 151, pp. 104567-104567
Closed Access | Times Cited: 114
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Martin H. Voss, Cinta Hierro, Rebecca S. Heist, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 9, pp. 2699-2707
Open Access | Times Cited: 113
KIAA1549
Aline Paixão Becker, Cristovam Scapulatempo‐Neto, Adriana Cruvinel Carloni, et al.
Journal of Neuropathology & Experimental Neurology (2015) Vol. 74, Iss. 7, pp. 743-754
Open Access | Times Cited: 94
Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
Brendan Farrell, Alexander L. Breeze
Biochemical Society Transactions (2018) Vol. 46, Iss. 6, pp. 1753-1770
Open Access | Times Cited: 92
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
Chiara Casadei, Nazlı Dizman, Giuseppe Schepisi, et al.
Therapeutic Advances in Medical Oncology (2019) Vol. 11
Open Access | Times Cited: 88
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 609-617
Open Access | Times Cited: 67
Page 1 - Next Page

Scroll to top